Correction: Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4

Tao Jiang; Fujue Wang; Lianjie Hu; Xiaomin Cheng; Yuhuan Zheng; Ting Liu; Yongqian Jia

doi:10.18632/oncotarget.25302

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4

PDF | How to cite

Oncotarget. 2018; 9:21629-21629. https://doi.org/10.18632/oncotarget.25302

Metrics: PDF 2117 views | ?

Tao Jiang^1,2,*, Fujue Wang^1,4,*, Lianjie Hu^1,4, Xiaomin Cheng^1,3, Yuhuan Zheng^1,4, Ting Liu^1,4 and Yongqian Jia^1,4

¹Department of Hematology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China
²Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu 610072, Sichuan, China
³Department of Hematology, Chengdu Military General Hospital, Chengdu 610083, Sichuan, China
⁴Laboratory of Hematology, West China Hospital of Sichuan University, Tianfu Life Science Park, Chengdu 610041, Sichuan, China
^*These authors have contributed equally to this work

Published: April 20, 2018

This article has been corrected: The equal contribution note has been added to Drs. Jiang and Wang.

Tao Jiang^1,2,*, Fujue Wang^1,4,*, Lianjie Hu^1,4, Xiaomin Cheng^1,3, Yuhuan Zheng^1,4, Ting Liu^1,4 and Yongqian Jia^1,4

^*These authors have contributed equally to this work

Original article: Oncotarget. 2017; 8:77586-77594. DOI: https://doi.org/10.18632/oncotarget.20659.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25302

Publication Alerts

Post-Publication Promotion

Corrections:

Correction: Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4